HALOZYME THERAPEUTICS, INC. Net Change in Cash
HALOZYME THERAPEUTICS, INC. (HALO) reported Net Change in Cash of $27.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $175.59M, a 190.33% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $60.48M, a 30.74% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $46.26M.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$137.81M.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $20.57M.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$2.52M.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$116.33M, a 200.74% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $115.48M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.57M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $175.59M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $20.57M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $303.81M 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | -$53.99M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $60.48M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$2.52M 10-K · filed 2026-02-17 | |||
| 2024-09-30 | $35.95M 10-Q · filed 2025-11-03 | |||
| 2024-06-30 | $69.49M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $46.26M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$116.33M 10-K · filed 2026-02-17 | |||
| 2023-09-30 | $39.53M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | -$13.53M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$137.81M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $115.48M 10-K · filed 2025-02-18 | |||
| 2022-09-30 | $28.44M 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$27.79M 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$884.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$28.98M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | $343.98M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $299.26M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $351.75M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $27.52M 10-K · filed 2023-02-21 | |||
| 2020-09-30 | -$54.44M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $13.43M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$15.36M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $62.24M 10-K · filed 2022-02-22 | |||
| 2019-09-30 | $1.27M 10-Q · filed 2020-11-02 | |||
| 2019-06-30 | $9.11M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $2.66M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$110.80M 10-K · filed 2021-02-23 | |||
| 2018-09-30 | -$113.72M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$113.57M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | -$70.73M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $101.98M 10-K · filed 2020-02-24 | |||
| 2017-09-30 | $97.63M 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $47.98M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | -$21.58M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $23.47M 10-K · filed 2019-02-21 | |||
| 2016-09-30 | $17.91M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | $17.94M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | -$18.10M 10-K · filed 2018-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |